KEGG   DRUG: Trastuzumab deruxtecanHelp
Entry
D11529                      Drug                                   

Name
Trastuzumab deruxtecan (USAN/INN);
Trastuzumab deruxtecan (genetical recombination) (JAN);
Fam-trastuzumab deruxtecan-nxki;
Enhertu (TN)
Product
Formula
C6460H9972N1724O2014S44. (C52H57FN9O13)8
Exact mass
153607.1079
Mol weight
153701.9811
Remark
Product: D11529<US>
Efficacy
Antineoplastic
  Disease
Breast cancer (HER2 positive) [DS:H00031]
Comment
Antibody-drug conjugate
Target
ERBB2 (HER2, CD340) [HSA:2064] [KO:K05083]
TOP1 [HSA:7150] [KO:K03163]
  Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2 (HER2, CD340)
     D11529  Trastuzumab deruxtecan (USAN/INN) <US>
 Enzymes
  Isomerases (EC5)
   DNA topoisomerase
    TOP1
     D11529  Trastuzumab deruxtecan (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11529
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11529
BRITE hierarchy
Other DBs
CAS: 1826843-81-5
PubChem: 384585505
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system